10-OR: In Women with Prior Gestational Diabetes Mellitus, the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Improves Glucose Tolerance Irrespective of Body Weight Loss after Five Years of Treatment, but Effects Are Lost after Wash-Out

Abstract

Women with prior gestational diabetes mellitus (pGDM) are at high risk of developing type 2 diabetes (T2D). We evaluated whether treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, for 5 years reduces the risk of T2D in these women. Overweight women with pGDM were randomized to an active arm (treatment with liraglutide 1.8 mg once-daily for 5 years) or a control arm (placebo for 1 year and thereafter no treatment) (Table). At baseline, one year and five years, a 4-hour 75 g-oral glucose tolerance test (OGTT) and an intravenous isoglycemic glucose infusion (IIGI) was conducted. Liraglutide-treated women completed both an OGTT on drug and after one week of wash-out. Glucose tolerance improved in liraglutide-treated women after five years of treatment vs. placebo (Table). However, this effect was not maintained after one-week wash-out of liraglutide. No significant difference was observed in body weight, fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c) between groups after five years of treatment. In conclusion, after five years of treatment, liraglutide showed no significant effect on body weight, FPG or HbA1c but continued to exert a beneficial effect on oral glucose tolerance in women with pGDM when on drug. After wash-out this effect was lost. Disclosure E. S. Andersen: None. P. Damm: Advisory Panel; Self; Novo Nordisk A/S, Other Relationship; Self; Novo Nordisk A/S. F. K. Knop: Advisory Panel; Self; MSD Corporation, Novo Nordisk A/S, Sanofi, Consultant; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S, Pharmacosmos, Zealand Pharma A/S, Research Support; Self; Novo Nordisk A/S, Zealand Pharma A/S, Speaker’s Bureau; Self; AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, MSD Corporation, Novo Nordisk A/S. T. Vilsboll: Consultant; Self; Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Lilly Diabetes, Merck Sharp & Dohme Corp., Mundipharma International, Novo Nordisk, Sanofi, Sun Pharmaceutical Industries Ltd. S. Foghsgaard: None. L. Vedtofte: None. M. H. Pedersen: None. J. Forman: None. E. R. Mathiesen: Advisory Panel; Self; Novo Nordisk, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; Novo Nordisk, Sanofi-Aventis. J. Svare: None. J. J. Holst: Consultant; Self; Novo Nordisk, Other Relationship; Self; Antag Therapeutics, Bainan Biotech, MSD Corporation, Novo Nordisk, Other Relationship; Spouse/Partner; Antag Therapeutics, Bainan Biotech, Synklino ApS. T. D. Clausen: None.